Literature DB >> 10563435

Ongoing protocols for non-AIDS primary central nervous system lymphoma.

K Hoang-Xuan1, J Y Delattre.   

Abstract

The optimal treatment for primary central nervous system lymphoma (PCNSL) remains undefined. In this paper, we review the main multi-institutional ongoing protocols for PCNSL. Most of the current protocols evaluate the efficacy of combination high-dose methotrexate-based chemotherapy and brain irradiation in phase II studies. Some trials focus on chemotherapy alone as initial treatment, in order to minimize long-term cognitive sequellae. Because old age appears as a major predisposing factor for combined RT and CT neurotoxicity some specific protocols have been proposed to this particular population.

Entities:  

Mesh:

Year:  1999        PMID: 10563435     DOI: 10.1023/a:1006266821574

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.

Authors:  M Reni; A J Ferreri; M P Garancini; E Villa
Journal:  Ann Oncol       Date:  1997-03       Impact factor: 32.976

2.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.

Authors:  D F Nelson; K L Martz; H Bonner; J S Nelson; J Newall; H D Kerman; J W Thomson; K J Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases.

Authors:  A A Gabbai; F H Hochberg; R M Linggood; R Bashir; K Hotleman
Journal:  J Neurosurg       Date:  1989-02       Impact factor: 5.115

4.  Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.

Authors:  E M Bessell; F Graus; J A Punt; J L Firth; D T Hope; A J Moloney; A Lopez-Guillermo; S Villa
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

5.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

6.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

7.  Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results.

Authors:  L Cher; J Glass; G R Harsh; F H Hochberg
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

Review 8.  Current management of primary central nervous system lymphoma.

Authors:  L M Deangelis
Journal:  Oncology (Williston Park)       Date:  1995-01       Impact factor: 2.990

9.  Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.

Authors:  E A Neuwelt; D L Goldman; S A Dahlborg; J Crossen; F Ramsey; S Roman-Goldstein; R Braziel; B Dana
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

10.  Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.

Authors:  R J Freilich; J Y Delattre; A Monjour; L M DeAngelis
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

View more
  1 in total

1.  A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.

Authors:  Nan Zhou; Xiaolin Xu; Yueming Liu; Yaxing Wang; Wenbin Wei
Journal:  Eye (Lond)       Date:  2021-07-01       Impact factor: 4.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.